Patients, hospitals, oncology centres, pharmacies, and pharmaceutical distributors in South Africa may search online for Ibyra 100mg Tablets when looking for olaparib-based oncology treatment. Ibyra 100mg Tablets contain olaparib 100mg, a prescription PARP inhibitor used under specialist medical supervision for certain types of cancer.
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical exporter supplying oncology medicines to international markets, including South Africa, subject to applicable prescription, import, and regulatory requirements.
Ibyra 100mg Tablets – Composition and Strength
Ibyra 100mg Tablets contain:
Active ingredient: Olaparib
Strength: 100mg
Dosage form: Oral tablet
Therapeutic category: Oncology / PARP inhibitor
Olaparib works by inhibiting PARP enzymes involved in repairing damaged DNA. In certain cancer cells with defects in DNA-repair pathways, blocking PARP can interfere with cancer-cell survival. The medicine is therefore used for specific cancer indications determined by the treating oncologist.
Uses of Olaparib 100mg in Cancer Treatment
Olaparib may be prescribed for selected patients with cancers such as ovarian, breast, pancreatic, or prostate cancer, depending on the cancer type, genetic or biomarker status, previous treatment, and applicable clinical guidelines.
Treatment decisions should always be made by a qualified oncology specialist. Patients should not start, stop, or change olaparib treatment without medical advice.
Ibyra 100mg Tablets Supply to South Africa
Cordium Pharmaceuticals Pvt Ltd supports international pharmaceutical sourcing from India for eligible healthcare and pharmaceutical buyers. Ibyra 100mg Tablets can be considered for enquiries from South African pharmaceutical distributors, hospitals, oncology centres, and other authorised healthcare procurement channels.
For international supply, product availability, documentation, packaging, shipping arrangements, and import requirements can vary according to destination-country regulations. Buyers should confirm that the product can be legally imported and supplied in South Africa before placing an order.
Safety and Medical Supervision
Ibyra 100mg is a prescription oncology medicine and should be used only according to the treating physician's instructions. Reported adverse effects associated with olaparib include nausea, fatigue, vomiting, decreased appetite, diarrhoea, dizziness, and changes in blood-cell counts.
Doctors may monitor blood counts and other clinical parameters during treatment. Patients should also disclose other medicines, supplements, kidney or liver conditions, pregnancy plans, and breastfeeding status to their healthcare professional.
Why Choose Cordium Pharmaceuticals for Oncology Medicine Supply?
Cordium Pharmaceuticals Pvt Ltd provides international pharmaceutical sourcing and export support from India. Our focus includes oncology medicines for authorised pharmaceutical and healthcare procurement channels.
South African buyers searching for Ibyra 100mg Tablets, Olaparib 100mg Tablets, Olaparib supplier from India, oncology medicine exporter India, or Olaparib 100mg wholesale supply can contact Cordium Pharmaceuticals for product availability, quotation, and export-related information.
Frequently Asked Questions
What is Ibyra 100mg Tablet?
Ibyra 100mg Tablet contains olaparib 100mg, a prescription PARP inhibitor used for certain cancer indications.
Is Ibyra 100mg available for export to South Africa?
Availability depends on product stock, applicable export requirements, and South African import regulations. Buyers can contact Cordium Pharmaceuticals for current supply information.
Who should prescribe Ibyra 100mg?
It should be prescribed and monitored by a qualified healthcare professional, particularly an oncology specialist.
How can South African buyers enquire about Ibyra 100mg Tablets?
Authorised pharmaceutical distributors, hospitals, and healthcare procurement organisations can contact Cordium Pharmaceuticals Pvt Ltd for supply and export enquiries.
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical exporter supplying oncology medicines to international markets, including South Africa, subject to applicable prescription, import, and regulatory requirements.
Ibyra 100mg Tablets – Composition and Strength
Ibyra 100mg Tablets contain:
Active ingredient: Olaparib
Strength: 100mg
Dosage form: Oral tablet
Therapeutic category: Oncology / PARP inhibitor
Olaparib works by inhibiting PARP enzymes involved in repairing damaged DNA. In certain cancer cells with defects in DNA-repair pathways, blocking PARP can interfere with cancer-cell survival. The medicine is therefore used for specific cancer indications determined by the treating oncologist.
Uses of Olaparib 100mg in Cancer Treatment
Olaparib may be prescribed for selected patients with cancers such as ovarian, breast, pancreatic, or prostate cancer, depending on the cancer type, genetic or biomarker status, previous treatment, and applicable clinical guidelines.
Treatment decisions should always be made by a qualified oncology specialist. Patients should not start, stop, or change olaparib treatment without medical advice.
Ibyra 100mg Tablets Supply to South Africa
Cordium Pharmaceuticals Pvt Ltd supports international pharmaceutical sourcing from India for eligible healthcare and pharmaceutical buyers. Ibyra 100mg Tablets can be considered for enquiries from South African pharmaceutical distributors, hospitals, oncology centres, and other authorised healthcare procurement channels.
For international supply, product availability, documentation, packaging, shipping arrangements, and import requirements can vary according to destination-country regulations. Buyers should confirm that the product can be legally imported and supplied in South Africa before placing an order.
Safety and Medical Supervision
Ibyra 100mg is a prescription oncology medicine and should be used only according to the treating physician's instructions. Reported adverse effects associated with olaparib include nausea, fatigue, vomiting, decreased appetite, diarrhoea, dizziness, and changes in blood-cell counts.
Doctors may monitor blood counts and other clinical parameters during treatment. Patients should also disclose other medicines, supplements, kidney or liver conditions, pregnancy plans, and breastfeeding status to their healthcare professional.
Why Choose Cordium Pharmaceuticals for Oncology Medicine Supply?
Cordium Pharmaceuticals Pvt Ltd provides international pharmaceutical sourcing and export support from India. Our focus includes oncology medicines for authorised pharmaceutical and healthcare procurement channels.
South African buyers searching for Ibyra 100mg Tablets, Olaparib 100mg Tablets, Olaparib supplier from India, oncology medicine exporter India, or Olaparib 100mg wholesale supply can contact Cordium Pharmaceuticals for product availability, quotation, and export-related information.
Frequently Asked Questions
What is Ibyra 100mg Tablet?
Ibyra 100mg Tablet contains olaparib 100mg, a prescription PARP inhibitor used for certain cancer indications.
Is Ibyra 100mg available for export to South Africa?
Availability depends on product stock, applicable export requirements, and South African import regulations. Buyers can contact Cordium Pharmaceuticals for current supply information.
Who should prescribe Ibyra 100mg?
It should be prescribed and monitored by a qualified healthcare professional, particularly an oncology specialist.
How can South African buyers enquire about Ibyra 100mg Tablets?
Authorised pharmaceutical distributors, hospitals, and healthcare procurement organisations can contact Cordium Pharmaceuticals Pvt Ltd for supply and export enquiries.
Keywords
